Therapeutics News

The Dupixent prefilled pen has been approved by the FDA for all Dupixent indications in patients aged 12 years and older, Regeneron announced in a press release.

Prolonged use of systemic retinoids was safe and effective for the treatment of patients with moderate to severe Darier disease, according to study results presented at the American Academy of Dermatology virtual meeting.

As the world continues to struggle with the COVID-19 pandemic, new symptoms of the virus continue to be identified. One such symptom, purple or red lesions on the toes and hands, has been dubbed “COVID toes” and has gained attention over recent weeks.

Sofpironium bromide gel reduced hyperhidrosis severity and demonstrated an acceptable safety profile in a phase 2 study detailed in Journal of the American Academy of Dermatology.

In response to the COVID-19 outbreak, the American Academy of Dermatology has issued a guidance on the use of biologic agents. The document was created on March 18, 2020, and is subject to change as the pandemic develops.

Among patients with psoriasis who showed an inadequate response to apremilast, etanercept was associated with strong response rates and patient-reported outcomes, according to a recently published study.

The FDA granted breakthrough therapy designation to baricitinib to treat patients with alopecia areata, according to a press release from Eli Lilly and Incyte.

Pregnancies exposed to oral or topical terbinafine had no increased risk for major malformations or spontaneous abortion compared with unexposed pregnancies, according to a study.

Aldeyra Therapeutics will prioritize its ocular disease programs while placing on hold clinical development in other fields as part of a strategic prioritization program, according to a press release.

Skin quality and degree of laxity are more important than chronological age when choosing a candidate for fourth-generation non-microneedling monopolar radiofrequency for skin tightening, according to a consensus recommendation statement.